How to Get Trulicity in Hawaii: Telehealth, Prescriptions, and Pharmacies

What Is Trulicity and Why Do Hawaii Physicians Prescribe It?

Dulaglutide (Trulicity) is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for glycemic control in adults with type 2 diabetes and, separately, to reduce major adverse cardiovascular events (MACE) in adults with established cardiovascular disease or multiple risk factors. Hawaii physicians prescribe it because the drug combines glycemic efficacy with a cardiovascular outcomes benefit confirmed in a large randomized trial.

The REWIND trial (N=9,901, median follow-up 5.4 years) published in The Lancet in 2019 found that dulaglutide 1.5 mg once weekly reduced the composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death by 12% relative to placebo (hazard ratio 0.88 to 95% CI 0.79 to 0.99, P=0.026) [1]. REWIND enrolled a broader, lower-risk population than earlier GLP-1 cardiovascular trials, making the findings applicable to the wider type 2 diabetes population that Hawaiian clinicians treat every day.

The FDA originally approved dulaglutide in September 2014 for type 2 diabetes management and later added the cardiovascular risk-reduction indication in 2020 [2]. The approved dosing range runs from 0.75 mg once weekly up to 4.5 mg once weekly, delivered via a prefilled single-use autoinjector pen.

Hawaii has one of the highest rates of diabetes-related complications in Pacific Islander and Native Hawaiian communities. The CDC's 2023 National Diabetes Statistics Report notes that Native Hawaiian and Pacific Islander adults carry a disproportionate burden of type 2 diabetes prevalence and complication rates compared with the national average [3]. That epidemiologic context makes access to effective GLP-1 therapy a genuine public-health issue for the state.

Hawaii Telehealth Laws and Trulicity Prescribing

Hawaii permits telehealth prescribing of controlled and non-controlled medications, including dulaglutide, without a mandatory in-person visit first. Dulaglutide is a Schedule-exempt prescription drug, so no DEA-waiver or in-person examination requirement applies under Hawaii Revised Statutes Chapter 453.

The American Diabetes Association's 2024 Standards of Care in Diabetes state: "Telemedicine for diabetes management is effective and should be used to improve access to care, particularly in underserved and geographically isolated communities" [4]. Hawaii's island geography makes that guidance directly relevant. Patients on Maui, the Big Island, Kauai, Molokai, or Lanai often face limited endocrinology access; telehealth bridges that gap.

A qualifying Hawaii telehealth encounter for a Trulicity prescription must include a synchronous audio-visual or audio-only visit (Hawaii allows audio-only for established patients under HRS 453-1.3), a documented medical history, a review of current labs, and a written prescription transmitted electronically to a licensed Hawaii pharmacy or a mail-order pharmacy with Hawaii licensure.

Clinicians licensed in Hawaii who practice exclusively via telehealth can prescribe dulaglutide to any Hawaii resident. Clinicians licensed in another state cannot legally prescribe to Hawaii residents unless they also hold a Hawaii license or a Hawaii multi-state compact registration (Hawaii is a member of the Interstate Medical Licensure Compact for physicians and the Nurse Licensure Compact for RNs, though prescriptive NP authority still requires individual Hawaii licensure in most cases).

The FDA's guidance on telehealth prescribing does not restrict non-controlled outpatient drugs like dulaglutide to in-person evaluation [5]. HealthRX providers hold active Hawaii licenses and can initiate a dulaglutide prescription at the first synchronous visit.

Required Labs Before Getting a Trulicity Prescription in Hawaii

Before any licensed prescriber issues a dulaglutide prescription, a baseline lab panel is medically necessary. Hawaii telehealth providers typically require results no older than 6 to 12 months.

The minimum required panel includes:

• Hemoglobin A1c to confirm type 2 diabetes diagnosis (ADA diagnostic threshold: A1c 6.5% or higher) and to establish a baseline for response monitoring [4]
• Comprehensive metabolic panel (CMP) including serum creatinine and eGFR, because dulaglutide requires dose caution below eGFR 15 mL/min/1.73m2 per the FDA label [2]
• Fasting lipid panel to assess cardiovascular risk and guide concurrent statin therapy decisions
• TSH to screen for thyroid disease, because GLP-1 receptor agonists carry a boxed warning regarding medullary thyroid carcinoma risk in patients with personal or family history of MEN2 or MTC [2]
• Urine albumin-to-creatinine ratio (UACR) to assess diabetic nephropathy stage per ADA Standards of Care Section 11 [6]

The ADA recommends repeating A1c every 3 months when therapy is being adjusted and every 6 months once stable [4]. Hawaii Quest patients or self-pay patients can obtain these labs through Quest Diagnostics or LabCorp locations across Oahu, Maui, and the Big Island, with results typically available within 24 to 48 hours. Some HealthRX patients complete at-home finger-stick A1c kits before their telehealth visit to accelerate the timeline.

Patients with a personal or family history of MEN2 syndrome or medullary thyroid carcinoma are absolutely contraindicated for dulaglutide regardless of lab values [2].

Who Can Prescribe Trulicity in Hawaii

Hawaii law grants prescriptive authority for non-controlled drugs like dulaglutide to several provider types. Knowing which credentials to look for saves time when choosing a telehealth platform.

Medical Doctors (MD) and Doctors of Osteopathic Medicine (DO) hold full prescriptive authority under HRS Chapter 453. Endocrinologists, primary care physicians, and internal medicine specialists routinely prescribe dulaglutide.

Advanced Practice Registered Nurses (APRN) with prescriptive authority can prescribe dulaglutide independently in Hawaii. Hawaii is a full-practice authority state for APRNs under HRS 457-8.6, meaning an APRN does not need physician collaboration or co-signature to issue a Trulicity prescription [7]. This substantially expands the telehealth provider pool for Hawaii residents.

Physician Assistants (PA-C) can prescribe under a supervising physician agreement per HRS Chapter 453. Most Hawaii telehealth platforms with PA providers have a supervising MD on the license, satisfying this requirement.

The table below summarizes prescribing authority at a glance for Hawaii dulaglutide prescribers:

| Provider Type | Independent Rx Authority | Notes | |---|---|---| | MD / DO | Yes | Full authority, HRS Ch. 453 | | APRN (full-practice) | Yes | No MD co-sign needed, HRS 457-8.6 | | PA-C | Supervised | Requires supervising MD agreement | | CNM | Yes (within scope) | Full authority for metabolic comorbidities |

The Endocrine Society Clinical Practice Guideline on Type 2 Diabetes recommends initiating GLP-1 receptor agonist therapy in patients with type 2 diabetes and established or high cardiovascular risk, regardless of whether A1c is at target, as an atherosclerosis risk-reduction strategy [8].

How Hawaii Prior Authorization Works for Trulicity

Most commercial insurance plans covering Hawaii residents require prior authorization (PA) before they will cover brand-name Trulicity. Hawaii Medicaid (Med-QUEST) does not currently cover dulaglutide for type 2 diabetes, so Med-QUEST enrollees must pay out-of-pocket or seek manufacturer assistance programs.

For commercial plans, a typical PA packet includes:

1. Documentation of type 2 diabetes diagnosis with A1c value and date
2. Evidence that at least one first-line agent (usually metformin 1 to 000 mg twice daily for 90 days or longer) was tried and produced insufficient glycemic control or was contraindicated
3. Prescriber attestation of cardiovascular risk factors or established ASCVD (strengthens medical necessity under most Hawaii plan formularies)
4. Recent lab results (A1c, CMP, lipids)

The American Diabetes Association's 2024 Standards of Care explicitly state that GLP-1 receptor agonists with proven cardiovascular benefit should be used "independent of A1c" in patients with type 2 diabetes and ASCVD or high cardiovascular risk [4]. Including that guideline citation in a PA appeal letter frequently overturns initial denials from Hawaii commercial insurers.

Eli Lilly's Trulicity Savings Card can reduce out-of-pocket cost to as low as $25 per month for commercially insured patients. Uninsured Hawaii patients may qualify for the Lilly Cares Foundation patient assistance program, which provides free Trulicity to eligible low-income applicants [2].

PA processing times in Hawaii typically run 3 to 5 business days for standard review. Urgent PA requests, when supported by documented cardiovascular risk, can resolve in 24 to 72 hours under Hawaii Insurance Division prompt-pay rules.

Trulicity Pharmacies in Hawaii: Retail, Mail-Order, and 503A Compounding

Retail pharmacies across Oahu (including Longs Drugs, CVS, Walgreens, Costco Pharmacy, and Walmart Pharmacy), Maui, Kauai, and the Big Island stock brand-name Trulicity in standard doses. Inventory can be inconsistent for the 3.0 mg and 4.5 mg strengths, so calling ahead is advisable.

Mail-order pharmacies licensed in Hawaii, including Express Scripts, OptumRx, and Alto Pharmacy, ship Trulicity in temperature-controlled packaging directly to any Hawaii address. Transit from mainland distribution centers to neighbor islands typically adds one business day compared to Oahu delivery. FDA cold-chain guidance requires dulaglutide to be shipped at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) and protected from direct sunlight [5].

503A compounding pharmacies licensed in Hawaii may compound dulaglutide analogs for individual patients under a valid prescription from a licensed Hawaii prescriber. The FDA's current enforcement policy on GLP-1 compounding distinguishes between 503A patient-specific compounders (permitted under state pharmacy law) and 503B outsourcing facilities (subject to federal manufacturing standards). Hawaii-licensed 503A pharmacies can legally prepare dulaglutide formulations when the commercially manufactured product is unavailable or when a prescriber documents a specific patient need [5]. Patients should verify that any 503A pharmacy holds a current Hawaii Board of Pharmacy license before ordering.

The FDA's April 2025 determination removed semaglutide and tirzepatide from the shortage list but did not address dulaglutide compounding in the same action, so 503A dulaglutide compounding remains available under existing state law for Hawaii patients [5].

Step-by-Step: Getting Trulicity Through a Hawaii Telehealth Provider

The sequence below reflects the actual clinical workflow HealthRX uses for Hawaii-based patients seeking dulaglutide.

Step 1: Order baseline labs. Schedule or upload A1c, CMP, TSH, lipid panel, and UACR. Quest Diagnostics has 11 patient service centers on Oahu alone, with locations on Maui and the Big Island. Results are digitally shareable within 24 to 48 hours.

Step 2: Book a synchronous telehealth visit. A Hawaii-licensed HealthRX provider conducts a video or audio visit reviewing your diagnosis, lab results, medication history, contraindications (MEN2 history, gastroparesis, pancreatitis history), and current medications. The visit typically runs 20 to 30 minutes.

Step 3: Receive a written prescription. If dulaglutide is clinically appropriate, the provider transmits an electronic prescription to your preferred Hawaii retail pharmacy or a licensed mail-order pharmacy.

Step 4: Insurance or self-pay routing. The HealthRX care team initiates prior authorization for commercially insured patients simultaneously with prescription transmission. Self-pay patients receive a GoodRx coupon code or are directed to the Lilly Cares program.

Step 5: First injection. Once pharmacy dispensing is confirmed, a HealthRX nurse provides a short injection-technique training via video. The FDA-approved Trulicity prescribing information recommends injecting into the abdomen, thigh, or upper arm, rotating sites weekly [2].

Step 6: 4-week follow-up. A brief telehealth check-in at 4 weeks confirms tolerability, addresses nausea (the most common side effect, reported in up to 21% of patients in clinical trials at the 1.5 mg dose), and determines whether dose escalation to 1.5 mg is appropriate [2].

Transferring an Existing Trulicity Prescription to Hawaii

Patients moving to Hawaii with an active Trulicity prescription from another state cannot simply refill at a Hawaii pharmacy on an out-of-state prescription. Hawaii pharmacy law requires prescriptions for ongoing therapy to be issued by a provider licensed in Hawaii or to be transferred through a formal pharmacist-to-pharmacist transfer process for non-controlled drugs.

The practical solution is a telehealth re-evaluation with a Hawaii-licensed provider. Because dulaglutide is not a controlled substance, no DEA transfer rules apply. The American Association of Clinical Endocrinology (AACE) 2023 Diabetes Management Algorithm supports continuity of GLP-1 therapy during transitions of care, noting that abrupt discontinuation of GLP-1 receptor agonists results in glycemic rebound within 4 to 8 weeks [9].

Bring the following documents to your Hawaii telehealth re-evaluation to minimize delays:

• Most recent A1c result (within 6 months)
• Current Trulicity dose and duration of therapy
• Pharmacy records showing refill history
• Any prior authorization approval letters from the previous insurer

A Hawaii-licensed provider can issue a new prescription at the same dose on the day of the visit, and a Hawaii pharmacy can begin filling immediately. Mail-order from the mainland is usually faster for neighbor island patients.

Side Effects, Monitoring, and When to Contact Your Prescriber

Dulaglutide's most common side effects are gastrointestinal: nausea, diarrhea, vomiting, and abdominal pain. In the AWARD-11 trial (N=1,842), which evaluated higher doses, nausea occurred in 31% of patients at the 3.0 mg dose vs. 12% of placebo patients, with most episodes resolving within the first 4 to 8 weeks [10]. Eating smaller portions, avoiding high-fat meals, and injecting on a consistent weekly day all reduce nausea severity.

Rare but serious adverse effects requiring immediate contact with your prescriber include:

• Acute pancreatitis (severe, persistent abdominal pain radiating to the back)
• Hypoglycemia (most likely when combined with sulfonylureas or insulin, not as a standalone agent)
• Acute kidney injury secondary to dehydration from GI side effects
• Allergic reaction (rash, swelling, difficulty breathing at the injection site)

The FDA boxed warning covers the theoretical risk of thyroid C-cell tumors observed in rodent studies, though no causal link has been established in humans as of the REWIND trial's 5.4-year follow-up [1]. Patients should still report any neck mass, hoarseness, or difficulty swallowing promptly.

Monitoring after initiation follows ADA 2024 recommendations: A1c every 3 months for the first year, then every 6 months once stable [4]. eGFR and UACR monitoring annually or per nephrologist guidance [6]. Blood pressure monitoring at each visit given the modest blood-pressure-lowering effect of dulaglutide (approximately 2 to 3 mmHg systolic reduction vs. placebo in REWIND) [1].

Cost of Trulicity in Hawaii Without Insurance

Brand-name Trulicity without insurance runs approximately $900 to $950 for a 4-pen monthly supply at Hawaii retail pharmacies as of mid-2025, consistent with mainland pricing. GoodRx coupons reduce that figure to approximately $780 to $820 at Costco Pharmacy on Oahu, which historically offers the lowest cash prices among chain pharmacies in the state.

The Lilly Insulin Value Program is separate from the Trulicity Savings Card. Eligible commercially insured patients pay $25 per month with the savings card. The Lilly Cares Foundation offers free Trulicity to uninsured patients with household income at or below 400% of the federal poverty level. Applications process in 2 to 4 weeks; providers can submit bridge prescriptions for a 30-day supply through samples or a pharmacy bridge program while the application is pending.

Hawaii Med-QUEST (Medicaid) does not currently list dulaglutide on its preferred drug list for type 2 diabetes. Med-QUEST enrollees who meet the REWIND-consistent cardiovascular risk profile may submit a formulary exception request, supported by the REWIND citation and the ADA 2024 cardiovascular risk guidance, though approval rates for this exception in Hawaii remain low [4].